| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17408 R73017 |
Madley-Dowd_SE (Gabapentin) (Controls exposed to LTG) (Mixed indications), 2024 | Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes |
1.22 [1.02;1.45] excluded (control group) |
39/864 243/5,035 | 282 | 864 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17411 R73035 |
Madley-Dowd_SE (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 | Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.13 [0.82;1.54] | 39/864 147,608/2,651,210 | 147,647 | 864 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17410 R73029 |
Madley-Dowd_SE (Gabapentin) (Controls unexposed, sibling) (Mixed indications), 2024 | Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | sibling excluded | Adjustment: Yes |
0.90 [0.50;1.61] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17281 R72361 |
Madley-Dowd_UK (Gabapentin) (Controls exposed to LTG) (Mixed indications), 2024 | Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median 4.93 (3.11-7.46) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
0.92 [0.43;1.96] excluded (control group) |
9/564 14/939 | 23 | 564 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17265 R72362 |
Madley-Dowd_UK (Gabapentin) (Controls unexposed, general pop) (Mixed indications), 2024 | Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median 4.93 (3.11-7.46) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.77 [0.92;3.43] | 9/564 4,794/514,066 | 4,803 | 564 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17273 R72363 |
Madley-Dowd_UK (Gabapentin) (Controls unexposed, sibling) (Mixed indications), 2024 | Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median 4.93 (3.11-7.46) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | sibling excluded | Adjustment: Yes |
3.44 [0.96;12.35] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8543 R48898 |
Bromley, 2016 | Maladaptive behavior: Hyperactivity (BASC) (5-9 years old) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No extrapolated (cont. endpoint) | 0.87 [0.30;2.52] | -/14 -/55 | - | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.20 [0.91;1.58] | 152,450 | 1,442 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Gabapentin) (Controls unexposed, general pop) (Mixed indications; 2: Gabapentin) (Controls unexposed, general pop) (Mixed indications;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 17408, 17410, 17281, 17273